Clindax-B

 1%+5% Topical Gel
Opsonin Pharma Ltd.

20 gm tube: ৳ 350.00

10 gm tube: ৳ 150.00

Indications

Approved Indications:

  • Acne Vulgaris (Mild to Moderate):
    Topical combination of clindamycin (1%) and benzoyl peroxide (2.5%–5%) is indicated for the treatment of inflammatory and non-inflammatory lesions of acne vulgaris in patients aged 12 years and older.

Clinically Accepted Off-Label Uses:

  • Truncal Acne:
    Widely accepted use on the chest and back in addition to facial acne.
  • Acne Fulminans (Adjunctive):
    In combination with systemic therapy for mild cases of acne fulminans with inflammation.
  • Maintenance Therapy:
    Used after oral therapy (e.g., isotretinoin) to prevent recurrence.
Dosage & Administration

Recommended Formulation Strengths:

  • Clindamycin 1% + Benzoyl Peroxide 2.5%, 3.75%, or 5% gel/lotion

Adults and Adolescents (≥12 years):

  • Apply a thin layer once daily to affected skin areas after washing and drying.
  • Use on intact skin only.
  • Avoid application to eyes, lips, mouth, nostrils, and mucous membranes.

Pediatrics (<12 years):

  • Safety and efficacy not established for patients under 12 years of age.

Elderly:

  • Use with caution. No dosage adjustment required.

Renal/Hepatic Impairment:

  • Topical route limits systemic absorption; no dosage adjustment needed.
    However, monitor in hepatic dysfunction due to clindamycin component.

Administration Notes:

  • Wash hands after application.
  • Do not use occlusive dressings unless directed.
  • Apply sunscreen when going outdoors; benzoyl peroxide may increase sun sensitivity.
Mechanism of Action (MOA)

Clindamycin, a lincosamide antibiotic, binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis. This leads to bacteriostatic effects against acne-associated bacteria like Cutibacterium acnes.
Benzoyl Peroxide is a topical oxidizing agent with keratolytic, comedolytic, and bactericidal properties. It releases oxygen free radicals that destroy C. acnes, reduces follicular hyperkeratinization, and decreases inflammation. The combination enhances acne treatment by reducing bacterial resistance and targeting multiple acne pathophysiological mechanisms.

Pharmacokinetics
  • Absorption:
    • Clindamycin: ~10% systemic absorption through skin; converted to active metabolite lincomycin.
    • Benzoyl Peroxide: Absorbed through skin and rapidly metabolized to benzoic acid, which is excreted in urine.
  • Distribution:
    Local effect; systemic distribution is minimal with proper use.
  • Metabolism:
    • Clindamycin: Hepatic metabolism.
    • Benzoyl Peroxide: Converted to benzoic acid in the skin.
  • Elimination:
    • Clindamycin metabolites excreted in urine and feces.
    • Benzoic acid excreted renally.
  • Half-life:
    Not clinically significant due to limited systemic exposure.
  • Onset of Action:
    Initial improvement seen within 2–4 weeks; full effects by 8–12 weeks.
Pregnancy Category & Lactation
  • Pregnancy:
    Clindamycin is Category B (topical); benzoyl peroxide is not assigned a category but is considered low risk due to minimal systemic absorption. Use only if clearly needed during pregnancy.
  • Lactation:
    Both components have minimal systemic absorption when used topically.
    Recommendation: Use with caution; avoid application to chest or nipple area to prevent infant exposure.
  • Caution:
    Insufficient data for high-strength benzoyl peroxide combinations in pregnancy; safer alternatives may be preferred.
Therapeutic Class
  • Primary Class: Topical Antiacne Agent
  • Subclass: Combination of Topical Antibiotic (Clindamycin) + Keratolytic/Bactericidal Agent (Benzoyl Peroxide)
Contraindications
  • Hypersensitivity to clindamycin, lincomycin, benzoyl peroxide, or formulation excipients
  • History of antibiotic-associated colitis (e.g., pseudomembranous colitis)
  • Broken, irritated, or sunburned skin at application site
Warnings & Precautions
  • Clostridioides difficile–associated Diarrhea (CDAD):
    Rare but serious systemic absorption of clindamycin may cause CDAD.
  • Allergic Reactions:
    Rash, urticaria, anaphylaxis (rare)
  • Skin Irritation:
    Dryness, erythema, peeling, stinging or burning may occur; discontinue if severe.
  • Photosensitivity:
    Benzoyl peroxide may increase UV sensitivity; use sunscreen.
  • Bleaching Effects:
    May bleach hair, clothing, bedding, or towels.
  • Prolonged Use:
    May lead to bacterial resistance to clindamycin; limit long-term use.
Side Effects

Common (Local):

  • Dryness
  • Erythema
  • Skin peeling
  • Burning or stinging
  • Itching

Less Common:

  • Oily skin or redness worsening
  • Photosensitivity

Serious (Rare):

  • Allergic contact dermatitis
  • Anaphylaxis
  • Diarrhea or colitis (from clindamycin systemic absorption)

Onset:

  • Irritation typically occurs in the first 2 weeks, often improves with continued use.
  • Serious effects are rare and typically dose-independent.
Drug Interactions

Drug–Drug Interactions:

  • Topical Retinoids (e.g., tretinoin, adapalene):
    May increase irritation; apply at different times (e.g., one in AM, other in PM).
  • Oral Clindamycin or Lincomycin:
    Avoid concurrent use to reduce risk of systemic toxicity or resistance.

Drug–Cosmetic Interaction:

  • Avoid products with alcohol, astringents, or abrasives that may worsen irritation.

Enzyme Systems:

  • Not metabolized via CYP450; minimal systemic interaction.

Drug–Alcohol Interaction:

  • No direct interaction, but alcohol-containing topical agents may increase skin dryness.
Recent Updates or Guidelines
  • American Academy of Dermatology (AAD):
    Recommends combination therapy (antibiotic + benzoyl peroxide) as first-line for mild to moderate inflammatory acne to prevent resistance.
  • Updated Product Labeling (Recent Years):
    Emphasized precautions regarding photosensitivity and contact dermatitis; clarified pregnancy and lactation considerations.
  • Global Acne Guidelines (GOLD, 2023):
    Reaffirmed that combination therapy reduces monotherapy antibiotic resistance and improves acne control outcomes.
Storage Conditions
  • Temperature:
    Store at 20°C to 25°C (68°F to 77°F).
    Excursions permitted between 15°C and 30°C.
  • Humidity & Light:
    Protect from moisture and direct light.
  • Handling Precautions:
    • Do not freeze.
    • Keep away from eyes, mouth, and mucous membranes.
    • Wash hands after use.
    • Avoid contact with hair or fabrics due to bleaching potential.
  • Shelf Life:
    Follow product-specific expiration. Discard after recommended period (usually 3 months after opening).
Available Brand Names